Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Bilateral Lateral OFC rTMS in Obsessive Compulsive Disorder

NCT04934007 · tracked via the Priya Life Science France tracker
Phase
Not applicable
Started
2021-09-06
Last updated
2026-01-13

Condition(s) studied

Obsessive-Compulsive Disorder

Investigational drug(s) / intervention(s)

rTMS Treatment

rTMS Treatment: 1 Hz rTMS

Study summary

According to the literature the lateral part of the Orbito Frontal Cortex (lOFC) is a relevant bilateral target for repetitive Trans-cranial Magnetic Stimulation (rTMS) in Obsessive Compulsive Disorder (OCD). Both hemispheres are concerned in terms of target.

Eligibility

Sex
ALL
Min age
18 Years
Max age
65 Years
Healthy volunteers
No
Inclusion Criteria: * Age: Participants will be both males and females, 18-65 years of age included. * diagnosis of OCD * all the patients must have failed to respond to at least two different pharmacological treatment used for at least 6 weeks * Affiliation to a social security system (recipient or assignee), * Signed written inform consent form Exclusion Criteria: * The exclusion criteria are a diagnosis of another psychiatric disorder (except for anxious disorders), a diagnosis of a significant active medical illness, pregnancy or other neurological illness * In accordance with the safety criteria for rTMS, patients with a history of seizure or bearing pacemakers, mobile metal implants, implanted medical pumps, or metal clips placed inside the skull will also be excluded * The patients won't be allowed to change their medication during the trial. The treatment must be stable at least 3 week before day 0. * Female subject who is pregnant, or of child-bearing age, sexually active and not using reliable contraception or who is nursing, * Patient under curators * Patient hospitalized under duress * Patient unable to give his or hers informed consent

Primary outcome measure(s)

  • Yale Brown Obsessive Compulsive Scale score — baseline and 25 days
    Significant clinical change (≥ 25%) from baseline to two weeks after the treatment sequence, assessed by a significant reduction in YBOCS scores at day 25

Trial sites (2)

FacilityCityRegionStatus
Sorbonne University, Pitié-Salpêtrière Hospital Paris France Recruiting
Centre Hospitalier Henri Laborit Poitiers France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT04934007 on ClinicalTrials.gov ↗ ← All trials in France